154 related articles for article (PubMed ID: 24455971)
1. Relationship between human chorionic gonadotropin serum levels and the risk of ovarian hyperstimulation syndrome.
Johnson MD; Williams SL; Seager CK; Liu JH; Barker NM; Hurd WW
Gynecol Endocrinol; 2014 Apr; 30(4):294-7. PubMed ID: 24455971
[TBL] [Abstract][Full Text] [Related]
2. A novel oocyte maturation trigger using 1500 IU of human chorionic gonadotropin plus 450 IU of follicle-stimulating hormone may decrease ovarian hyperstimulation syndrome across all in vitro fertilization stimulation protocols.
Anaya Y; Mata DA; Letourneau J; Cakmak H; Cedars MI; Rosen MP
J Assist Reprod Genet; 2018 Feb; 35(2):297-307. PubMed ID: 29086322
[TBL] [Abstract][Full Text] [Related]
3. GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients.
Humaidan P; Polyzos NP; Alsbjerg B; Erb K; Mikkelsen AL; Elbaek HO; Papanikolaou EG; Andersen CY
Hum Reprod; 2013 Sep; 28(9):2511-21. PubMed ID: 23753114
[TBL] [Abstract][Full Text] [Related]
4. Severe early ovarian hyperstimulation syndrome following GnRH agonist trigger with the addition of 1500 IU hCG.
Seyhan A; Ata B; Polat M; Son WY; Yarali H; Dahan MH
Hum Reprod; 2013 Sep; 28(9):2522-8. PubMed ID: 23633553
[TBL] [Abstract][Full Text] [Related]
5. GnRH agonist with low-dose hCG (dual trigger) is associated with higher risk of severe ovarian hyperstimulation syndrome compared to GnRH agonist alone.
O'Neill KE; Senapati S; Maina I; Gracia C; Dokras A
J Assist Reprod Genet; 2016 Sep; 33(9):1175-84. PubMed ID: 27349252
[TBL] [Abstract][Full Text] [Related]
6. Effects of the ovulatory serum concentration of human chorionic gonadotropin on the incidence of ovarian hyperstimulation syndrome and success rates for in vitro fertilization.
Shapiro BS; Daneshmand ST; Garner FC; Aguirre M; Ross R; Morris S
Fertil Steril; 2005 Jul; 84(1):93-8. PubMed ID: 16009163
[TBL] [Abstract][Full Text] [Related]
7. A gonadotropin releasing hormone agonist trigger of ovulation with aggressive luteal phase support for patients at risk of ovarian hyperstimulation syndrome undergoing controlled ovarian hyperstimulation.
Liang IT; Huang HY; Wu HM; Wang HS; Yu HT; Huang SY; Chang CL; Soong YK
Taiwan J Obstet Gynecol; 2015 Oct; 54(5):583-7. PubMed ID: 26522115
[TBL] [Abstract][Full Text] [Related]
8. Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study.
Iliodromiti S; Blockeel C; Tremellen KP; Fleming R; Tournaye H; Humaidan P; Nelson SM
Hum Reprod; 2013 Sep; 28(9):2529-36. PubMed ID: 23873146
[TBL] [Abstract][Full Text] [Related]
9. Reducing the dose of human chorionic gonadotropin in high responders does not affect the outcomes of in vitro fertilization.
Schmidt DW; Maier DB; Nulsen JC; Benadiva CA
Fertil Steril; 2004 Oct; 82(4):841-6. PubMed ID: 15482757
[TBL] [Abstract][Full Text] [Related]
10. Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles.
Papanikolaou EG; Pozzobon C; Kolibianakis EM; Camus M; Tournaye H; Fatemi HM; Van Steirteghem A; Devroey P
Fertil Steril; 2006 Jan; 85(1):112-20. PubMed ID: 16412740
[TBL] [Abstract][Full Text] [Related]
11. Early and late presentation of the ovarian hyperstimulation syndrome: two distinct entities with different risk factors.
Lyons CA; Wheeler CA; Frishman GN; Hackett RJ; Seifer DB; Haning RV
Hum Reprod; 1994 May; 9(5):792-9. PubMed ID: 7929724
[TBL] [Abstract][Full Text] [Related]
12. Severe ovarian hyperstimulation syndrome modifies early maternal serum beta-human chorionic gonadotropin kinetics, but obstetrical and neonatal outcomes are not impacted.
Choux C; Barberet J; Ginod P; Cottenet J; Bruno C; Benzénine E; Sagot P; Fauque P
Fertil Steril; 2017 Oct; 108(4):650-658.e2. PubMed ID: 28911926
[TBL] [Abstract][Full Text] [Related]
13. Ultrasound and hematological changes during early luteal phase in women at high risk for developing ovarian hyperstimulation syndrome.
Lainas GT; Lainas TG; Venetis CA; Sfontouris IA; Zorzovilis IZ; Alexopoulou E; Tarlatzis BC; Kolibianakis EM
Ultrasound Obstet Gynecol; 2018 Jan; 51(1):126-133. PubMed ID: 29105961
[TBL] [Abstract][Full Text] [Related]
14. Clinical parameters of ovarian hyperstimulation syndrome following different hormonal triggers of oocyte maturation in IVF treatment.
Abbara A; Islam R; Clarke SA; Jeffers L; Christopoulos G; Comninos AN; Salim R; Lavery SA; Vuong TNL; Humaidan P; Kelsey TW; Trew GH; Dhillo WS
Clin Endocrinol (Oxf); 2018 Jun; 88(6):920-927. PubMed ID: 29446481
[TBL] [Abstract][Full Text] [Related]
15. Moderate-to-severe ovarian hyperstimulation syndrome: A retrospective multivariate logistic regression analysis in Chinese patients.
Ma T; Niu Y; Wei B; Xu L; Zou L; Che X; Wang X; Tang D; Huang R; Chen B
Adv Clin Exp Med; 2020 Jan; 29(1):85-90. PubMed ID: 31990458
[TBL] [Abstract][Full Text] [Related]
16. Prevention of severe ovarian hyperstimulation syndrome in IVF with or without ICSI and embryo transfer: a modified 'coasting' strategy based on ultrasound for identification of high-risk patients.
Al-Shawaf T; Zosmer A; Hussain S; Tozer A; Panay N; Wilson C; Lower AM; Grudzinskas JG
Hum Reprod; 2001 Jan; 16(1):24-30. PubMed ID: 11139531
[TBL] [Abstract][Full Text] [Related]
17. Predictive factors of early moderate/severe ovarian hyperstimulation syndrome in non-polycystic ovarian syndrome patients: a statistical model.
Ashrafi M; Bahmanabadi A; Akhond MR; Arabipoor A
Arch Gynecol Obstet; 2015 Nov; 292(5):1145-52. PubMed ID: 25920524
[TBL] [Abstract][Full Text] [Related]
18. The optimal length of 'coasting protocol' in women at risk of ovarian hyperstimulation syndrome undergoing in vitro fertilization.
Nardo LG; Cheema P; Gelbaya TA; Horne G; Fitzgerald CT; Pease EH; Brison DR; Lieberman BA
Hum Fertil (Camb); 2006 Sep; 9(3):175-80. PubMed ID: 17008270
[TBL] [Abstract][Full Text] [Related]
19. Circulatory dysfunction in asymptomatic in vitro fertilization patients. Relationship with hyperestrogenemia and activity of endogenous vasodilators.
Manau D; Balasch J; Arroyo V; Jiménez W; Fábregues F; Casamitjana R; Creus M; Vanrell JA
J Clin Endocrinol Metab; 1998 May; 83(5):1489-93. PubMed ID: 9589644
[TBL] [Abstract][Full Text] [Related]
20. Ovarian hyperstimulation syndrome in the 21st century: the role of gonadotropin-releasing hormone agonist trigger and kisspeptin.
Thomsen L; Humaidan P
Curr Opin Obstet Gynecol; 2015 Jun; 27(3):210-4. PubMed ID: 25811256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
